0000886163-17-000099.txt : 20170810
0000886163-17-000099.hdr.sgml : 20170810
20170810184039
ACCESSION NUMBER: 0000886163-17-000099
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170809
FILED AS OF DATE: 20170810
DATE AS OF CHANGE: 20170810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FOEHR MATTHEW W
CENTRAL INDEX KEY: 0001237556
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 171022602
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES RD #200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2017-08-09
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001237556
FOEHR MATTHEW W
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO
CA
92121
0
1
0
0
President and COO
Common Stock
2017-08-09
4
M
0
6100
9.97
A
101020
D
Common Stock
2017-08-09
4
S
0
6100
127.5121
D
94920
D
Common Stock
2017-08-09
4
M
0
850
9.97
A
95770
D
Employee Stock Option (right to buy)
9.97
2017-08-09
2017-08-09
4
M
0
6100
0.0
D
2021-04-18
Common Stock
6100
43935
D
Employee Stock Option (right to buy)
9.97
2017-08-09
2017-08-09
4
M
0
850
0.0
D
2021-04-18
Common Stock
850
43085
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.4774 to $127.8374, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.
By: Charles S. Berkman For: Matthew W. Foehr
2017-08-10